Feature | February 07, 2014

Transcatheter Pump May Aid Heart Failure Patients

Procyrion Aortix Ventricular Assist Device Hemodynamic Support Heart Failure
February 7, 2014 — Start-up company Procyrion Inc. is developing a catheter-deployed circulatory assist device intended for long-term use in the treatment of chronic heart failure. The 6-mm diameter Aortix device is narrower than a pencil and is delivered via a catheter in a minimally invasive outpatient procedure lasting about 10 minutes.
 
Currently, long-term mechanical circulatory support (MCS) is limited to large ventricular assist devices (VADs). These devices are mainly used in patients with late stage heart failure (HF). Procyrion is developing a percutaneous intra-aortic micro-axial fluid entrainment pump called Aortix intended for long-term MCS in patients with earlier stage HF.
 
Aortix has been successfully tested with computer models, on the bench top in mock flow loops and in vivo in large animal HF studies. In three porcine experiments conducted last year, the pump was deployed in the thoracic aorta by standard cardiac catheterization techniques and was anchored with self-expanding struts. Acute cardiac dysfunction was induced by infusing esmolol continuously. Pump support increased cardiac output (+10.4 percent), stroke volume (+8.9 percent), and ejection fraction (+10.8 percent) while decreasing cardiac stroke work (-10.8 percent) and afterload (-22.7 percent). Pump support enhanced renal perfusion through sustained increases in both renal artery flow (+36.4 percent) and pressure (+73.6 percent).
 
In a porcine model of acute HF, the catheter-based intra-aortic fluid entrainment pump improved hemodynamics and renal perfusion. These results suggest the pump could improve HF outcomes and patients' quality of life by resting the heart, promoting reverse remodeling and augmenting end-organ perfusion. The renal perfusion may help disrupt the cardiorenal syndrome cycle and improve HF treatment.
 
The company received the Commercialization award by the Gulf Coast Regional Center of Innovation and Commercialization in February 2013 and received a total of $1.5 million in assistance from the Texas Emerging Technology Fund.  
 
 
For more information: www.procyrion.com

Related Content

cardiac rehab, cardiac rehabilitation, CHF, heart failure

Congestive heart failure patient Dorothy Moore committed herself to cardiac rehabilitation and increasing the amount of exercise she did and was able to reverse her heart failure class. Patient engagement is key to improving CHF patient quality of life and outcomes without the use of drugs and devices.

Feature | Cardiac Rehabilitation| May 24, 2016 | Karen D. Walker, RN, MSN, and Stephanie Rejc, MS
Cardiac rehabilitation and exercise training has been shown to improve clinical status and outcomes in congestive hea
News | Heart Failure| May 23, 2016
May 23, 2016 — In a guideline update published last week, the American College of Cardiology, American Heart Associat
Bioventrix, Revivent-TC System, heart failure, first-in-man procedure
News | Heart Failure| May 19, 2016
BioVentrix announced the first-in-man use of its next-generation Revivent-TC System with an endovascular catheter-based...
News | Heart Failure| May 16, 2016
May 16, 2016 –To work towards a better method of diagnosis and treatment of...
News | Stem Cell Therapies| May 16, 2016
May 16,  2016 — Patients treated with processed autologous adipose-derived regenerative cells (ADRCs) injected into t
Medtronic, FDA approval, MR-conditional CRT-Ds, defibrillators, Amplia, Compia
Technology | Cardiac Resynchronization Therapy Devices (CRT)| May 11, 2016
Medtronic plc recently announced it received U.S. Food and Drug Administration (FDA) approval for the first and only...
LivaNova, SonR hemodynamic sensor, CRT, heart failure, RESPOND CRT trial, HRS 2016
News | Cardiac Resynchronization Therapy Devices (CRT)| May 10, 2016
The first-ever trial using new SonR hemodynamic sensor technology proves to be safely and effectively applied in...
atrial fibrillation risk, heart failure, African Americans, Hispanics, whites, HRS 2016
News | Atrial Fibrillation| May 09, 2016
May 9, 2016 — A new study presented at the Heart Rhythm Society’s 37th Annual Scientific Sessions, found that among p
Biotronik, FDA, MR Conditional CRT devices, Iperia HF-T, defibrillator, ProMRI
Technology | Cardiac Resynchronization Therapy Devices (CRT)| May 03, 2016
Biotronik announced U.S. Food and Drug Administration (FDA) approval of Iperia ProMRI HF-T, a cardiac resynchronization...
Overlay Init